Live Breaking News & Updates on Thoracic Medical Oncology

 E-Mail
(Singapore January 30, 2021 11:00 p.m. SPT/January 30, 2021 10:00 a.m. EST) Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Malignant mesothelioma is an intractable cancer, and no phase III trial has yet shown an improvement in overall survival following the standard first line chemotherapy doublet comprising pemetrexed and cisplatin or carboplatin since it was licensed in 2004.
Professor Dean Fennell, chair of Thoracic Medical Oncology at the University of Leicester in collaboration with Professor Gareth Griffiths and his team at the Southampton Clinical Trials Unit, University of Southampton, UK, presented results of the Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study, funded by Cancer Research UK/Stand Up To Cancer. The investigator-led, placebo-cont ....

United Kingdom , Gareth Griffiths , Giorgio Scagliotti , University Of Leicester , University Of Southampton , Eastern Cooperative Oncology Group , International Association , Lung Cancer World Conference , Dean Fennell , Thoracic Medical Oncology , Professor Gareth Griffiths , Southampton Clinical Trials Unit , Checkpoint Blockade , Relapsed Mesothelioma , Cancer Research United , Lung Cancer , Thoracic Oncology , ஒன்றுபட்டது கிஂக்டம் , கரேத் கிரிஃபித்ஸ் , பல்கலைக்கழகம் ஆஃப் லெய்செஸ்டர் , பல்கலைக்கழகம் ஆஃப் சவுத்தாம்ப்டன் , கிழக்கு கூட்டுறவு புற்றுநோயியல் குழு , சர்வதேச சங்கம் , நுரையீரல் புற்றுநோய் உலகம் மாநாடு , டீன் ஃபெநல் , தொராசி மருத்துவ புற்றுநோயியல் ,